Jan 17, 2006
Merus BV Closes Series A Financing
Utrecht, The Netherlands, January 17, 2006 - Merus B.V., a privately held biomedical company, today announced the completion of a financial package with Aglaia Oncology Seed Fund B.V.
Older news
Sep 27, 2011
Merus launches MeMo, a transgenic mouse for improved therapeutic human monoclonal antibodies
Utrecht, The Netherlands, September 27, 2011 – Merus announced today that it has completed the construction of a single-light chain transgenic mouse for the generation of therapeutic human monoclonal antibodies.
May 16, 2011
Merus receives grant for breast cancer antibody therapy
Merus and ChromaCon receive a € 1.8 million project grant for the discovery and development of bispecific antibodies for therapy of advanced breast cancer
Jan 5, 2011
Merus receives grant for colon cancer antibody therapy
Merus receives € 0.75 million grant for the discovery and development of OligoclonicsTM antibody therapy for colon cancer
Jun 2, 2010
Merus Announces Publication of the Generation of Single, Clonal Cell lines
Press release
Jan 29, 2010
Press release
Oct 5, 2007
Issuance of a cornerstone patent covering the expression of antibody mixtures
Utrecht, The Netherlands, October 5, 2007 - Merus B.V. announced the issuance of an important patent by the United States Patent and Trademark Office.
Jan 17, 2006
Merus BV Closes Series A Financing
Utrecht, The Netherlands, January 17, 2006 - Merus B.V., a privately held biomedical company, today announced the completion of a financial package with Aglaia Oncology Seed Fund B.V.
Jun 10, 2004
Driebergen, The Netherlands - Dutch biotechnology company Crucell N.V.
Feb 10, 2004
Merus b.v. Licenses Oligoclonicsâ„¢ Production Technology for Therapeutic Antibody Mixtures
Driebergen, The Netherlands - Merus b.v. today announced that it has concluded an agreement with Crucell Holland B.V. to license from...